# An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

> **NCT06480552** · PHASE1 · RECRUITING · sponsor: **Teva Branded Pharmaceutical Products R&D LLC** · enrollment: 240 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** TEV-56278
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06480552
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-22
- **Primary completion:** 2029-05-26
- **Final completion:** 2031-02-25
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06480552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06480552, "An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06480552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*